Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bhatt

Showing results (471-480 of 486) with videos related to

Pageof 49
Sort By:
BJU International|April 30, 2022
LEARN: A multi-centre, cross-sectional evaluation of Urology teaching in UK medical schoolsAlexander Ng, Vinson Wai-Shun Chan, Aqua Asif, et al.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Advances|July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective StudyMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Transplantation and Cellular Therapy|July 21, 2022
Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic MalignancyCatherine J Lee, Tao Wang, Karen Chen, et al.
Transplantation and Cellular Therapy|January 19, 2024
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation RecipientsAnthony D Sung, Thuy Koll, Shannon H Gier, et al.
Blood Advances|November 21, 2025
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 StudyAndrew S Artz, Brent R Logan, Wael Saber, et al.
Leukemia & Lymphoma|February 27, 2020
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapyRory M Shallis, Maximilian Stahl, Wei Wei, et al.
Leukemia|March 6, 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyMaximilian Stahl, Rory M Shallis, Wei Wei, et al.
Blood Advances|March 18, 2025
Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704Mohamed L Sorror, Wael Saber, Brent R Logan, et al.
Pageof 49

Showing results (471-480 of 486) with videos related to

Sort By:
Pageof 49
BJU International|April 30, 2022
LEARN: A multi-centre, cross-sectional evaluation of Urology teaching in UK medical schoolsAlexander Ng, Vinson Wai-Shun Chan, Aqua Asif, et al.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Advances|July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective StudyMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Transplantation and Cellular Therapy|July 21, 2022
Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic MalignancyCatherine J Lee, Tao Wang, Karen Chen, et al.
Transplantation and Cellular Therapy|January 19, 2024
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation RecipientsAnthony D Sung, Thuy Koll, Shannon H Gier, et al.
Blood Advances|November 21, 2025
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 StudyAndrew S Artz, Brent R Logan, Wael Saber, et al.
Leukemia & Lymphoma|February 27, 2020
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapyRory M Shallis, Maximilian Stahl, Wei Wei, et al.
Leukemia|March 6, 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyMaximilian Stahl, Rory M Shallis, Wei Wei, et al.
Blood Advances|March 18, 2025
Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704Mohamed L Sorror, Wael Saber, Brent R Logan, et al.
Pageof 49